SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 2, 2023
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of Incorporation)
|
|
|
|
|
(Commission File No.)
|
(IRS Employer Identification No.)
|
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (760 ) 931-9200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 |
Results of Operations and Financial Condition.
|
On November 2, 2023, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the
Company’s financial results for the quarter ended September 30, 2023. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“GAAP”),
the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects. The Company is presenting pro forma information
excluding non-cash compensation expense and the related tax effects because the Company believes it better enables financial statement users to assess and compare its historical performance and project its future operating results and cash flows.
A copy of the release is furnished with this report as an exhibit pursuant to “Item 2.02. Results of Operations and Financial Condition” of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583.
The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or
the Exchange Act, regardless of any general incorporation language in such filing.
| Item 9.01. |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
Press Release dated November 2, 2023.
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
|
Ionis Pharmaceuticals, Inc.
|
||
|
Dated: November 2, 2023
|
By:
|
/s/ Patrick R. O’Neil
|
|
Patrick R. O’Neil
|
||
|
Executive Vice President, Chief Legal
Officer and General Counsel
|
||
Exhibit 99.1
Ionis reports third quarter 2023 financial results
Olezarsen Phase 3 data showed significant triglyceride lowering, substantial reductions in acute pancreatitis attacks and
favorable safety and tolerability in patients with FCS; on track for regulatory filings in early 2024
Eplontersen marketing applications accepted for review in the EU and Canada; potential U.S. approval in December 2023
On track to achieve 2023 financial guidance
CARLSBAD, Calif., November 2, 2023 – Ionis Pharmaceuticals, Inc. (Nasdaq:
IONS) (the “Company”), today reported financial results for the third quarter of 2023.
“We continue to successfully execute on our strategy to deliver a steady cadence of potentially transformational medicines to patients,” said Brett P. Monia, Ph.D.,
chief executive officer of Ionis. “Eplontersen is on track for its first potential approval in the U.S. and is under regulatory review in the EU and Canada. We believe the positive efficacy and safety data coupled with an attractive
self-administration dosing profile positions eplontersen to be the preferred therapy in the largely underserved hereditary ATTR polyneuropathy population. We reported positive data from the olezarsen Phase 3 Balance study in patients with familial
chylomicronemia syndrome, showing statistically significant triglyceride lowering, substantial reductions in acute pancreatitis attacks and favorable safety and tolerability,
positioning olezarsen to be our first independent commercial launch. We also made additional progress across our wholly owned and partnered pipeline, and further expanded our rich Phase 3 pipeline with the advance of zilganersen for patients with
Alexander disease into Phase 3 development. Looking ahead, we expect to continue our positive momentum with the potential approval and launch of eplontersen and the Phase 3 data readout of donidalorsen in hereditary angioedema.”
Third Quarter 2023 Summary Financial Results:
|
Three months ended
September 30,
|
Nine months ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
(amounts in millions)
|
||||||||||||||||
|
Total revenue
|
$
|
144
|
$
|
160
|
$
|
463
|
$
|
435
|
||||||||
|
Operating expenses
|
$
|
287
|
$
|
219
|
$
|
811
|
$
|
637
|
||||||||
|
Operating expenses on a non-GAAP basis
|
$
|
261
|
$
|
195
|
$
|
732
|
$
|
562
|
||||||||
|
Loss from operations
|
$
|
(143
|
)
|
$
|
(59
|
)
|
$
|
(348
|
)
|
$
|
(202
|
)
|
||||
|
Loss from operations on a non-GAAP basis
|
$
|
(117
|
)
|
$
|
(35
|
)
|
$
|
(269
|
)
|
$
|
(127
|
)
|
||||
1
Financial Highlights
| • |
Revenue continued to be substantial and sustained, with revenues of $144 million and $463 million in the three and nine months ended September 30, 2023, reflecting a 10% decrease
and 6% increase compared to the same periods last year, respectively, driven by the timing of certain partner payments
|
| • |
Operating expenses increased in the three and nine months ended September 30, 2023 compared to the same periods last year, primarily due to strategic investments to bring eplontersen, olezarsen and donidalorsen to patients
|
| • |
Cash and short-term investments of $2.2 billion as of September 30, 2023 enables continued investments to drive increasing value
|
| • |
Reaffirmed 2023 financial guidance
|
Near-Term Commercial Opportunities and Late-Stage Pipeline Highlights
| • |
Achieved multiple milestones with eplontersen:
|
| o |
Eplontersen is under regulatory review by the European Medicines Agency (EMA) and Health Canada for the
treatment of hereditary ATTR polyneuropathy (ATTRv-PN)
|
| o |
The EMA granted orphan drug designation to eplontersen for the treatment of ATTR in the EU
|
| o |
Published positive data from the Phase 3 NEURO-TTRansform study in patients with ATTRv-PN in the Journal
of the American Medical Association (JAMA) showing eplontersen halted measures of disease progression and continuously improved quality of life at 35-, 66- and 85-weeks
|
| o |
Presented positive new data showing continued benefit in secondary endpoints from the Phase 3 NEURO-TTRansform study in patients with ATTRv-PN at the European ATTR Amyloidosis
(EU-ATTR) meeting
|
| o |
Presented positive exploratory data from a pre-defined cardiac sub-population of patients in NEURO-TTRansform showing improvement in cardiac function and structure compared to
external placebo at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
|
| o |
Completed enrollment of the Phase 3 CARDIO-TTRansform study of eplontersen in patients with ATTR cardiomyopathy (ATTR-CM), the largest study ever conducted in ATTR-CM; on track for
data readout as early as H1:2025
|
| • |
Reported positive data from the Phase 3 Balance study of olezarsen in patients with familial chylomicronemia syndrome (FCS)
|
| o |
Olezarsen demonstrated robust, dose-dependent reductions in APOCIII, statistically significant reductions in triglycerides, substantial reductions in acute pancreatitis attacks and a favorable safety and tolerability profile
|
| o |
On track to file for regulatory approval in the U.S. and EU in early 2024
|
| • |
The FDA granted orphan drug designation to donidalorsen for the treatment of patients with hereditary angioedema (HAE); on track for data readout in the Phase 3 OASIS-HAE study in
H1:2024
|
| • |
Advanced zilganersen (GFAP) into Phase 3 development for the treatment of patients with Alexander disease
|
2
| • |
The FDA granted orphan drug designation to ulefnersen (FUS) for the treatment of patients with FUS-ALS
|
Partnered Program Highlights
| • |
GSK reported positive data from the Phase 2b B-Together study of bepirovirsen followed by pegylated interferon in patients with chronic hepatitis B virus (HBV)
|
| • |
Reported positive interim data from the ongoing Phase 2 study of IONIS-FB-LRx in patients with immunoglobulin A nephropathy (IgAN)
|
| • |
Biogen reported positive data from the Phase 1/2 study of IONIS-MAPTRx (BIIB080) in patients with Alzheimer’s disease
|
| • |
Completed enrollment in the Phase 1/2 HALOS study of ION582 (BIIB121) in patients with Angelman syndrome
|
| • |
Entered a new agreement with Roche to advance two novel RNA-targeted programs for Alzheimer’s disease and Huntington’s disease
|
3
Third Quarter 2023 Financial Results
“Our year-to-date financial results keep us on track to achieve our 2023 guidance as we execute on a strategy to unlock next-level value,” said Elizabeth L. Hougen,
chief financial officer of Ionis. “Our strong financial foundation includes more than $2B in cash, significant royalty revenue with SPINRAZA, and substantial and sustained R&D revenue from multiple partners. We are well positioned to continue
investing in our key priorities to drive future positive cash flow, including advancing our go-to-market activities, growing our wholly owned pipeline and optimizing new cutting-edge technologies for future medicines. We look forward to the
potential U.S. eplontersen ATTRv-PN approval next month followed closely by launch. Together with our partner, AstraZeneca, we believe we are well positioned to identify new
patients to further grow the market and become the treatment of choice for this population that remains largely underserved by current therapies.”
Revenue
Ionis’ revenue was comprised of the following:
|
Three months ended
September 30,
|
Nine months ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Revenue:
|
(amounts in millions)
|
|||||||||||||||
|
Commercial revenue:
|
||||||||||||||||
|
SPINRAZA royalties
|
$
|
67
|
$
|
62
|
$
|
179
|
$
|
175
|
||||||||
|
Other commercial revenue:
|
||||||||||||||||
|
TEGSEDI and WAYLIVRA revenue, net
|
8
|
6
|
25
|
23
|
||||||||||||
|
Licensing and royalty revenue
|
9
|
5
|
26
|
25
|
||||||||||||
|
Total commercial revenue
|
84
|
73
|
230
|
223
|
||||||||||||
|
Research and development revenue:
|
||||||||||||||||
|
Amortization from upfront payments
|
18
|
18
|
47
|
54
|
||||||||||||
|
Milestone payments
|
16
|
15
|
90
|
60
|
||||||||||||
|
License fees
|
5
|
35
|
25
|
37
|
||||||||||||
|
Other services
|
5
|
1
|
11
|
6
|
||||||||||||
|
Collaborative agreement revenue
|
44
|
69
|
173
|
157
|
||||||||||||
|
Eplontersen joint development revenue
|
16
|
18
|
60
|
55
|
||||||||||||
|
Total research and development revenue
|
60
|
87
|
233
|
212
|
||||||||||||
|
Total revenue
|
$
|
144
|
$
|
160
|
$
|
463
|
$
|
435
|
||||||||
Commercial revenue for the three and nine months ended September 30, 2023 included $67 million and $179 million from SPINRAZA royalties, respectively, which were
essentially flat compared to the same periods last year reflecting SPINRAZA’s resilience against emerging competition. Ionis’ commercial revenue in the three and nine months ended September 30, 2023 also included royalties from the U.S. launch of
QALSODY.
R&D revenue decreased for the three months ended September 30, 2023 and increased for the nine months ended September 30, 2023 compared to the same periods last
year due to the timing of certain partner payments, including the $35 million license fee for IONIS-FB-LRx that Ionis earned from Roche in the three months ended September 30, 2022.
4
Operating Expenses
Ionis’ operating expenses increased in the three and nine months ended September 30, 2023 compared to the same periods in 2022, consistent with expectations. As Ionis
advanced its robust pipeline, study costs increased compared to the same periods in 2022 as most of the Company’s Phase 3 studies are either fully enrolled or approaching full enrollment,
resulting in higher R&D expenses year over year. Ionis’ SG&A expenses also increased year over year primarily due to launch preparation activities for eplontersen, olezarsen and donidalorsen.
Balance Sheet
As of September 30, 2023, Ionis’ cash, cash equivalents and short-term investments increased to $2.2 billion compared to $2.0 billion at December 31, 2022 primarily
due to the $500 million Ionis received from Royalty Pharma in January 2023. Ionis’ working capital also increased over the same period primarily due to the Company’s higher cash and short-term investments balance. In the first quarter of 2023, the Company recorded a long-term liability for future royalties due to Royalty Pharma. In June 2023, Ionis issued $575 million of senior convertible notes due in June 2028 with an interest rate of 1.75%. The Company used the majority of the proceeds to repurchase $504 million of
its 0.125% convertible notes.
Webcast
Management will host a conference call and webcast to discuss Ionis’ third quarter 2023 results at 11:30 a.m. Eastern time on Thursday, November 2, 2023. Interested
parties may access the webcast here. A webcast replay will be available for a limited time at the same address. To access the Company’s third quarter 2023 earnings slides
click here.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed
medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in
genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com or follow us on Twitter @ionispharma.
Ionis’ Forward-looking Statement
This press release includes forward-looking statements regarding Ionis’ business, financial guidance and the therapeutic and commercial potential of QALSODY
(tofersen), SPINRAZA (nusinersen), TEGSEDI (inotersen), WAYLIVRA (volanesorsen), eplontersen, olezarsen, donidalorsen, zilganersen, ulefnersen, pelacarsen, bepirovirsen, IONIS-FB-LRx, Ionis' technologies and Ionis’ other products in development. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an
at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the
endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such
forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on
these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2022, and most recent Form 10-Q, which are on file with the
Securities and Exchange Commission. Copies of these and other documents are available from the Company.
5
In this press release, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our” and “us” all refer to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics® is a registered trademark of Akcea
Therapeutics, Inc. TEGSEDI® is a registered trademark of Akcea Therapeutics, Inc. WAYLIVRA® is a registered trademark of Akcea Therapeutics, Inc. QALSODYTM is a trademark of Biogen. SPINRAZA® is a
registered trademark of Biogen.
Ionis Investor Contact:
D. Wade Walke, Ph.D.
info@ionisph.com 760-603-2331
Ionis Media Contact:
David Polk, J.D.
ionis_ca@ionisph.com 760-603-4679
6
IONIS PHARMACEUTICALS, INC.
SELECTED FINANCIAL INFORMATION
Condensed Consolidated Statements of Operations
(In Millions, Except Per Share Data)
|
Three months ended,
September 30,
|
Nine months ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
(unaudited)
|
||||||||||||||||
|
Revenue:
|
||||||||||||||||
|
Commercial revenue:
|
||||||||||||||||
|
SPINRAZA royalties
|
$
|
67
|
$
|
62
|
$
|
179
|
$
|
175
|
||||||||
|
Other commercial revenue
|
17
|
11
|
51
|
48
|
||||||||||||
|
Total commercial revenue
|
84
|
73
|
230
|
223
|
||||||||||||
|
Research and development revenue:
|
||||||||||||||||
|
Collaborative agreement revenue
|
44
|
69
|
173
|
157
|
||||||||||||
|
Eplontersen joint development revenue
|
16
|
18
|
60
|
55
|
||||||||||||
|
Total research and development revenue
|
60
|
87
|
233
|
212
|
||||||||||||
|
Total revenue
|
144
|
160
|
463
|
435
|
||||||||||||
|
Expenses:
|
||||||||||||||||
|
Cost of sales
|
2
|
2
|
6
|
10
|
||||||||||||
|
Research, development and patent
|
215
|
183
|
643
|
525
|
||||||||||||
|
Selling, general and administrative
|
70
|
34
|
162
|
102
|
||||||||||||
|
Total operating expenses
|
287
|
219
|
811
|
637
|
||||||||||||
|
Loss from operations
|
(143
|
)
|
(59
|
)
|
(348
|
)
|
(202
|
)
|
||||||||
|
Other income (expense):
|
||||||||||||||||
|
Interest expense related to the sale of future royalties:
|
(18
|
)
|
-
|
(51
|
)
|
-
|
||||||||||
|
Other income (expense), net
|
20
|
12
|
68
|
(12
|
)
|
|||||||||||
|
Loss before income tax expense
|
(141
|
)
|
(47
|
)
|
(331
|
)
|
(214
|
)
|
||||||||
|
Income tax expense
|
(6
|
)
|
-
|
(26
|
)
|
(3
|
)
|
|||||||||
|
Net loss
|
$
|
(147
|
)
|
$
|
(47
|
)
|
$
|
(357
|
)
|
$
|
(217
|
)
|
||||
|
Basic and diluted net loss per share
|
$
|
(1.03
|
)
|
$
|
(0.33
|
)
|
$
|
(2.50
|
)
|
$
|
(1.53
|
)
|
||||
|
Shares used in computing basic and diluted net loss per share
|
143
|
142
|
143
|
142
|
||||||||||||
7
IONIS PHARMACEUTICALS, INC.
Reconciliation of GAAP to Non-GAAP Basis:
Condensed Consolidated Operating Expenses, Loss From Operations, and Net Loss
(In Millions)
|
Three months ended
September 30,
|
Nine months ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
(unaudited)
|
||||||||||||||||
|
As reported research, development and patent expenses according to GAAP
|
$
|
215
|
$
|
183
|
$
|
643
|
$
|
525
|
||||||||
|
Excluding compensation expense related to equity awards
|
(19
|
)
|
(18
|
)
|
(58
|
)
|
(55
|
)
|
||||||||
|
Non-GAAP research, development and patent expenses
|
$
|
196
|
$
|
165
|
$
|
585
|
$
|
470
|
||||||||
|
As reported selling, general and administrative expenses according to GAAP
|
$
|
70
|
$
|
34
|
$
|
162
|
$
|
102
|
||||||||
|
Excluding compensation expense related to equity awards
|
(7
|
)
|
(6
|
)
|
(22
|
)
|
(19
|
)
|
||||||||
|
Non-GAAP selling, general and administrative expenses
|
$
|
63
|
$
|
28
|
$
|
140
|
$
|
83
|
||||||||
|
As reported operating expenses according to GAAP
|
$
|
287
|
$
|
219
|
$
|
811
|
$
|
637
|
||||||||
|
Excluding compensation expense related to equity awards
|
(26
|
)
|
(24
|
)
|
(79
|
)
|
(75
|
)
|
||||||||
|
Non-GAAP operating expenses
|
$
|
261
|
$
|
195
|
$
|
732
|
$
|
562
|
||||||||
|
As reported loss from operations according to GAAP
|
$
|
(143
|
)
|
$
|
(59
|
)
|
$
|
(348
|
)
|
$
|
(202
|
)
|
||||
|
Excluding compensation expense related to equity awards
|
(26
|
)
|
(24
|
)
|
(79
|
)
|
(75
|
)
|
||||||||
|
Non-GAAP loss from operations
|
$
|
(117
|
)
|
$
|
(35
|
)
|
$
|
(269
|
)
|
$
|
(127
|
)
|
||||
|
As reported net loss according to GAAP
|
$
|
(147
|
)
|
$
|
(47
|
)
|
$
|
(357
|
)
|
$
|
(217
|
)
|
||||
|
Excluding compensation expense related to equity awards and related tax effects
|
(26
|
)
|
(24
|
)
|
(79
|
)
|
(75
|
)
|
||||||||
|
Non-GAAP net loss
|
$
|
(121
|
)
|
$
|
(23
|
)
|
$
|
(278
|
)
|
$
|
(142
|
)
|
||||
Reconciliation of GAAP to Non-GAAP Basis
As illustrated in the Selected Financial Information in this press release, non-GAAP operating expenses, non-GAAP loss from operations, and non-GAAP net loss were
adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effects. Compensation expense related to equity awards are non-cash. These measures are provided as supplementary information and are not a substitute
for financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows.
Further, the presentation of Ionis' non-GAAP results is consistent with how Ionis' management internally evaluates the performance of its operations.
8
IONIS PHARMACEUTICALS, INC.
Condensed Consolidated Balance Sheets
(In Millions)
|
September 30,2023
|
December 31,2022
|
|||||||
|
(unaudited)
|
||||||||
|
Assets:
|
||||||||
|
Cash, cash equivalents and short-term investments
|
$
|
2,236
|
$
|
1,987
|
||||
|
Contracts receivable
|
142
|
26
|
||||||
|
Other current assets
|
207
|
190
|
||||||
|
Property, plant and equipment, net
|
71
|
74
|
||||||
|
Right-of-use assets
|
174
|
182
|
||||||
|
Other assets
|
104
|
75
|
||||||
|
Total assets
|
2,934
|
$
|
2,534
|
|||||
|
Liabilities and stockholders’ equity:
|
||||||||
|
Other current liabilities
|
$
|
199
|
$
|
221
|
||||
|
Current portion of deferred contract revenue
|
205
|
91
|
||||||
|
1.75% convertible senior notes, net
|
562
|
-
|
||||||
|
0% convertible senior notes, net
|
625
|
622
|
||||||
|
0.125% convertible senior notes, net
|
44
|
545
|
||||||
|
Liability related to sale of future royalties, net
|
513
|
-
|
||||||
|
Long-term lease liabilities
|
173
|
178
|
||||||
|
Long-term obligations, less current portion
|
49
|
16
|
||||||
|
Long-term deferred contract revenue
|
249
|
288
|
||||||
|
Total stockholders’ equity
|
315
|
573
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
2,934
|
$
|
2,534
|
||||
9
Key 2023 Value Driving Events(1)
|
Regulatory Actions
|
|||
|
Program
|
Indication
|
Regulatory Action
|
Achieved
|
|
QALSODY
|
SOD1-ALS
|
NDA approval
|
 |
|
EU approval2
|
|||
|
Eplontersen (TTR)
|
ATTRv-PN
|
NDA approval
|
|
|
OUS filings
|
|
||
|
Key Clinical Data Events
|
|||
|
Program
|
Indication
|
Event
|
Achieved
|
|
Eplontersen (TTR)
|
ATTRv-PN
|
Phase 3 data (week 35, 66 & 85)
|
|
|
Olezarsen (APOCIII)
|
FCS
|
Phase 3 data
|
|
|
Donidalorsen (PKK)
|
HAE
|
Phase 2, OLE 1-year data
|
|
|
Donidalorsen (PKK)
|
HAE
|
Phase 2, OLE 2-year data
|
|
|
Bepirovirsen
|
HBV
|
Phase 2b B-Together data
|
|
|
IONIS-FB-LRx
|
IgAN
|
Phase 2 interim data
|
|
|
Enrollment Achievements
|
|||
|
Program
|
Indication
|
Event
|
Achieved
|
|
Eplontersen (TTR)
|
ATTR-CM
|
Phase 3 full enrollment
|
|
|
Donidalorsen (PKK)
|
HAE
|
Phase 3 full enrollment
|
|
|
IONIS-FB-LRx
|
GA
|
Phase 2 full enrollment
|
|
|
ION582 (UBE3A)
|
Angelman syndrome
|
Phase 1/2 full enrollment
|
|
|
Phase 3 Initiations
|
||
|
Program
|
Indication
|
Achieved
|
|
Zilganersen (GFAP)
|
Alexander disease
|
|
|
Bepirovirsen
|
HBV
|
|
|
IONIS-FB-LRx
|
IgAN
|
|
| (1) |
Timing expectations based on current assumptions and subject to change.
|
| (2) |
CHMP opinion anticipated in Q4:2023.
|
10